Tower Research Capital (TRC)’s Nabriva Therapeutics plc Ordinary Shares Ireland NBRV Stock Holding History

Tower Research Capital (TRC)’s Portfolio NBRV Stock Details NBRV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-8	Closed	–	–	6793
2022 Q4	$0	Buy	+8	New	+$18	﹤0.01%	6950
2020 Q3	–	Sell	-42	Closed	-$7K	–	5301
2020 Q2	$7K	Hold	42	–	–	﹤0.01%	4189
2020 Q1	$6K	Sell	42 -101	-71%	-$30.9K	﹤0.01%	2270
2019 Q4	$47K	Buy	143 +135	+1,688%	+$61.9K	﹤0.01%	1384
2019 Q3	$4K	Buy	+8	New	+$4.51K	﹤0.01%	3499
2019 Q1	–	Sell	-16	Closed	-$6K	–	4589
2018 Q4	$6K	Buy	+16	New	+$8.6K	﹤0.01%	2852
2018 Q3	–	Sell	-20	Closed	-$17K	–	4472
2018 Q2	$17K	Buy	20 +15	+300%	+$17.2K	﹤0.01%	2534
2018 Q1	$7K	Sell	5 -23	-82%	-$34K	﹤0.01%	2627
2017 Q4	$41K	Buy	+28	New	+$44.3K	0.01%	1491
2017 Q2	–	Sell	-2	Closed	-$6K	–	3755
2017 Q1	$6K	Buy	+2	New	+$4.86K	﹤0.01%	2141
2016 Q4	–	Hold	0	–	-$1K	–	4656
2016 Q3	–	Hold	0	–	–	–	3437
2016 Q2	–	Sell	-3	Closed	-$6K	–	5241
2016 Q1	$6K	Buy	3 +1	+50%	+$2.15K	﹤0.01%	2596
2015 Q4	$5K	Sell	2 -11	-85%	-$26.8K	﹤0.01%	3060
2015 Q3	$30K	Buy	+13	New	+$34.5K	﹤0.01%	1408

Other funds holding NBRV

VFA

Values First Advisors Gray, Tennessee $219M AUM 33.32% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Tower Research Capital (TRC)'s NBRV Position: Q1 2023 in Review

Tower Research Capital (TRC) sold out of Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) in Q1 2023, closing a stake of 8 shares.

Tower Research Capital (TRC) first reported a position in NBRV in Q3 2015 and held it in 13 quarters. The position peaked at $47K in Q4 2019. 12 funds tracked by Wall St. Rank hold NBRV as of Q1 2023.

Tower Research Capital (TRC) reported no remaining Nabriva Therapeutics plc Ordinary Shares Ireland position as of Q1 2023 after selling out during the quarter.
Tower Research Capital (TRC) sold 8 Nabriva Therapeutics plc Ordinary Shares Ireland shares in Q1 2023.
Tower Research Capital (TRC) first reported a position in Nabriva Therapeutics plc Ordinary Shares Ireland in Q3 2015 and held it in 13 quarters.
Tower Research Capital (TRC)'s Nabriva Therapeutics plc Ordinary Shares Ireland position peaked at $47K in Q4 2019.
12 funds tracked by Wall St. Rank held Nabriva Therapeutics plc Ordinary Shares Ireland as of Q1 2023.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2023, filed 9 May 2023.